Table 1.
Baseline characteristics
| Characteristic | ||
|---|---|---|
| Age, years, n (%) | ||
| Median, range | 55 (37–67) | |
| <60 | 12 | (80) |
| ≥60 | 3 | (20) |
| Female sex | 15 | |
| ECOG status, n (%) | ||
| 0 | 0 | (0) |
| 1 | 13 | (86.7) |
| 2 | 2 | (13.3) |
| Median follow-up time (months) | 6.3 (2.14–14.29) | |
| Sites of disease outside the CNS (not mutually exclusive)-no. | ||
| Lung | 11 | |
| Liver | 4 | |
| Bone | 6 | |
| Breast or chest wall | 2 | |
| Lymph nodes | 12 | |
| None | 2 | |
| Number of CNS lesions, n (%) | ||
| 1 | 1 | (6.7) |
| 2–5 | 11 | (73.3) |
| >5 | 3 | (20.0) |
| BM identified at baseline, n (%) | ||
| Progression during prior treatment | 8 | (53.3) |
| Routine examination | 5 | (33.3) |
| Neurological symptoms | 2 | (13.3) |
| Previous therapies*-no. | ||
| Trastuzumab | 11 | |
| Pertuzumab | 6 | |
| Lapatinib | 2 | |
| Other HER2 agents | 2 | |
| Chemotherapy lines in the metastatic setting†-no. (%) | ||
| 0 | 7 | (46.7) |
| 1 | 3 | (20.0) |
| 2 | 3 | (20.0) |
| ≥3 | 2 | (13.3) |
†Not including hormonal therapy.
*Including adjuvant therapy.